BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity

M. E. Cabanillas; A. Patel; B. P. Danysh; R. Dadu; S. Kopetz; G. Falchook

doi:10.1007/s12672-014-0207-9

BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity

M. E. Cabanillas, A. Patel, B. P. Danysh, R. Dadu, S. Kopetz, G. Falchook

Research output: Contribution to journal › Review article › peer-review

55 Scopus citations

Abstract

The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in patients with progressive, radioactive iodine–refractory BRAF-mutant papillary thyroid cancer suggest response rates of approximately 30–40 %. In this review, we discuss BRAF inhibitors in the context of thyroid cancer, the toxicities associated with BRAF inhibitors, and the suggested management of those toxicities. The management of vemurafenib and dabrafenib toxicities is applicable across all tumor types and may serve as a practical guide to their use.

Original language	English (US)
Pages (from-to)	21-36
Number of pages	16
Journal	Hormones and Cancer
Volume	6
Issue number	1
DOIs	https://doi.org/10.1007/s12672-014-0207-9
State	Published - Feb 2014

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Oncology
Endocrinology
Endocrine and Autonomic Systems
Cancer Research

MD Anderson CCSG core facilities

Clinical and Translational Research Center

Access to Document

10.1007/s12672-014-0207-9

Cite this

@article{5890ee3ba9f147939e6e610aae8ddd73,

title = "BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity",

abstract = "The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in patients with progressive, radioactive iodine–refractory BRAF-mutant papillary thyroid cancer suggest response rates of approximately 30–40 %. In this review, we discuss BRAF inhibitors in the context of thyroid cancer, the toxicities associated with BRAF inhibitors, and the suggested management of those toxicities. The management of vemurafenib and dabrafenib toxicities is applicable across all tumor types and may serve as a practical guide to their use.",

author = "Cabanillas, {M. E.} and A. Patel and Danysh, {B. P.} and R. Dadu and S. Kopetz and G. Falchook",

note = "Publisher Copyright: {\textcopyright} 2014, Springer Science+Business Media New York.",

year = "2014",

month = feb,

doi = "10.1007/s12672-014-0207-9",

language = "English (US)",

volume = "6",

pages = "21--36",

journal = "Hormones and Cancer",

issn = "1868-8497",

publisher = "Springer US",

number = "1",

}

TY - JOUR

T1 - BRAF Inhibitors

T2 - Experience in Thyroid Cancer and General Review of Toxicity

AU - Cabanillas, M. E.

AU - Patel, A.

AU - Danysh, B. P.

AU - Dadu, R.

AU - Kopetz, S.

AU - Falchook, G.

PY - 2014/2

Y1 - 2014/2

N2 - The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in patients with progressive, radioactive iodine–refractory BRAF-mutant papillary thyroid cancer suggest response rates of approximately 30–40 %. In this review, we discuss BRAF inhibitors in the context of thyroid cancer, the toxicities associated with BRAF inhibitors, and the suggested management of those toxicities. The management of vemurafenib and dabrafenib toxicities is applicable across all tumor types and may serve as a practical guide to their use.

AB - The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in patients with progressive, radioactive iodine–refractory BRAF-mutant papillary thyroid cancer suggest response rates of approximately 30–40 %. In this review, we discuss BRAF inhibitors in the context of thyroid cancer, the toxicities associated with BRAF inhibitors, and the suggested management of those toxicities. The management of vemurafenib and dabrafenib toxicities is applicable across all tumor types and may serve as a practical guide to their use.

UR - http://www.scopus.com/inward/record.url?scp=84925511788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925511788&partnerID=8YFLogxK

U2 - 10.1007/s12672-014-0207-9

DO - 10.1007/s12672-014-0207-9

M3 - Review article

C2 - 25467940

AN - SCOPUS:84925511788

SN - 1868-8497

VL - 6

SP - 21

EP - 36

JO - Hormones and Cancer

JF - Hormones and Cancer

IS - 1

ER -

BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this